HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is US Hemp Policy Heading For Farm Bill, Act III?

Executive Summary

It could take next farm bill, on lawmakers’ 2023 to-do list, to extinguish inferno of disagreement between FDA and regulated industries over lawful use of hemp-based ingredients in supplements as well as food and non-drug topicals. Before 2018 bill de-scheduled hemp, 2014 bill expanded access to hemp for research.

You may also be interested in...



Industry Looking For Details As Legislation Looks Likely On Hemp Ingredients' Use In Supplements

Whether lawmakers will favor legislation aligning with FDA’s thinking or hemp industry’s preferences isn’t known, says Jonathan Miller, US Hemp Roundtable general counsel. “We're feeling pretty confident that something's going to happen.”

Details Dished On Regulatory Pathway US FDA’s Developing For Lawful Hemp In Supplements

Pathway separate from FDA’s regulation of drugs and food would include rules on content limits, labeling, disclosure of ingredients– including assurances of no contaminants, and requirements to mitigate accidental ingestion.

Industry Asking Congress To Adjust Hemp Definition, Establish FDA Regulation 'Now"

Hemp Industries Association, National Industrial Hemp Council and US Hemp Roundtable say their “unprecedented alliance among 31 nonprofit hemp organizations portends promise for congressional enactment of the industry’s agenda.”

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153309

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel